Straits Times Index
3,307.90 -6.15 (-0.19%) S&P 500
5,312.22 +4.09 (+0.08%) Dow
39,860.74 +53.97 (+0.14%) Nasdaq
16,797.47 +2.59 (+0.02%) Bitcoin USD
70,165.02 +2,806.68 (+4.17%) CMC Crypto 200
1,531.18 +42.64 (+2.87%)
MedinCell S.A. (MEDCL.PA)
| Previous close | 14.34 |
| Open | 14.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 13.98 - 14.64 |
| 52-week range | 5.25 - 17.50 |
| Volume | |
| Avg. volume | 100,313 |
| Market cap | 409.314M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.01 |
| Earnings date | 25 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.40 |
Simply Wall St.Insider-Owned Growth Leaders On Euronext Paris For May 2024
Amidst a backdrop of fluctuating European markets, with France’s CAC 40 Index experiencing a slight decline, investors continue to seek stable growth opportunities. High insider ownership in growth companies on Euronext Paris is often viewed as a positive indicator of confidence in the company's future prospects, aligning well with current market conditions where discerning investment choices are paramount.
- Simply Wall St.
Euronext Paris Growth Companies With High Insider Ownership And Earnings Growth Up To 101%
Amidst a backdrop of mixed performances across major European markets, with France's CAC 40 Index experiencing a slight decline, investors continue to seek stable opportunities in growth-oriented companies. High insider ownership combined with promising earnings growth up to 101% can be particularly compelling in the current economic climate, signaling confidence from those who know the companies best.
Business WireMedincell Provides Update on Phase 3 mdc-CWM Clinical Trial
MONTPELLIER, France, May 14, 2024--Regulatory News: Medincell (Paris:MEDCL) today announced that the Phase 3 trial for F14 (mdc-CWM) being conducted by Arthritis Innovation Corporation (AIC) did not meet its primary endpoint of time-weighted AUC1 of pain intensity over 14 days when comparing treatment with multimodal analgesia (MMA) alone to MMA concurrent with a single dose of F14 administered in the knee at the time of Total Knee Replacement (TKR). The MMA control analgesia that every patient
